secwatch.observer — SEC 8-K summary
======================================

Issuer:     Picard Medical, Inc. (PMI)
CIK:        0002030617
Form:       8-K/A
Filed at:   2026-07-13T11:57:57+00:00
Accession:  0001437749-26-023381
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Picard Medical Q1 revenue up 85% YoY; gross margin improves to 24%
------------------------------------------------------------------

- Revenue for first three months of 2026 increased 85% YoY; U.S. revenue up 116%.
- Gross margin improved to 24% from -4% in 2025.
- Next-gen Emperor platform: pursuing FDA Breakthrough Device designation, IDE submission planned for 2028, clinical study in 2029.
- Interim CEO Richard Fang acknowledges recent leadership changes but reaffirms mission.
- Annual meeting set for July 17, 2026; proposals include director elections and capital structure amendments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030617/000143774926023381/0001437749-26-023381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030617/000143774926023381/pmi20260710_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-023381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer